EP0787182A2 - Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung - Google Patents
Embryonale herzmuskelzellen, ihre herstellung und ihre verwendungInfo
- Publication number
- EP0787182A2 EP0787182A2 EP95940117A EP95940117A EP0787182A2 EP 0787182 A2 EP0787182 A2 EP 0787182A2 EP 95940117 A EP95940117 A EP 95940117A EP 95940117 A EP95940117 A EP 95940117A EP 0787182 A2 EP0787182 A2 EP 0787182A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- muscle cells
- cells
- genes
- heart muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 claims abstract description 9
- 239000003550 marker Substances 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 8
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- 210000001519 tissue Anatomy 0.000 claims abstract description 8
- 230000004927 fusion Effects 0.000 claims abstract description 7
- 238000012546 transfer Methods 0.000 claims abstract description 7
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims abstract description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 6
- 210000004165 myocardium Anatomy 0.000 claims abstract description 6
- 229930193140 Neomycin Natural products 0.000 claims abstract description 5
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 229960004927 neomycin Drugs 0.000 claims abstract description 5
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 4
- 241000700584 Simplexvirus Species 0.000 claims abstract description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims abstract description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims abstract description 4
- 230000008828 contractile function Effects 0.000 claims abstract description 3
- 238000011835 investigation Methods 0.000 claims abstract description 3
- 108010065781 myosin light chain 2 Proteins 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- 230000006801 homologous recombination Effects 0.000 claims abstract 2
- 238000002744 homologous recombination Methods 0.000 claims abstract 2
- 239000013598 vector Substances 0.000 claims description 16
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 12
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 11
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000002574 poison Substances 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 108700005077 Viral Genes Proteins 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 210000002064 heart cell Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
- 239000013605 shuttle vector Substances 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 101710109784 Myosin regulatory light chain 12B Proteins 0.000 claims 1
- 101710092698 Myosin regulatory light chain 2 Proteins 0.000 claims 1
- 101710112127 Myosin regulatory light chain 2, skeletal muscle isoform Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000002242 embryoid body Anatomy 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001625 cardiomyogenic effect Effects 0.000 description 1
- 230000001756 cardiomyopathic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000014471 histiocytoid cardiomyopathy Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the invention relates to embryonic (cardiomyocytic and cardiomyoblastic) heart muscle cells, their production and their use, in particular for cell-mediated gene transplantation. Areas of application of the invention are medicine and genetic engineering.
- the aim of the invention is, starting from pluripotent embryonic stem cells (ESC) or primordial germ cells (EGC, Stewart et al, Dev. Biol. 161/1994 /, 626-628) after their differentiation into spontaneously pulsating cardiac cells embryonic (cardiomyocytic or cardio -myoblastic) cardiac muscle cells, which have largely identical properties with cardiac muscle tissue. These cells should be suitable for therapeutic use, possibly after additional genetic engineering changes.
- the object of the invention is to construct a vector system for modifying the stem cells and to develop a selection method for the transfected cells.
- the invention is implemented with modified embryonic stem cells according to claims 1 to 4, the vector systems according to claims 5 and 6 and the selection method according to claim 7.
- the scope of the invention also includes the use of the modified embryonic stem cells according to claims 8 to 10.
- the vectors according to the invention consist of the following components: a) the regulatory, 2.1 kb long DNA sequence of the ventricle-specific myosin light chain-2 (MLC-2v) as a promoter, the selectable marker gene ⁇ -galactosidase and the Reporter gene neomycin as a fusion gene "ßgeo" and the SV40-PolyA-Tail (pAA) and possibly a position for the inclusion of immortalizing genes. b) the regulatory DNA sequence of the herpes simplex virus thymidine kinase promoter (HSV-Tk), the selectable marker gene hygromycin and the SV40 polyA tail (pAA).
- Pluripotent embryonic stem cells are transfected with these vectors in vitro.
- the successfully transfected cells are selected in the first step with the help of hygromycin.
- Hygromycin-resistant cells are then differentiated into so-called embryoid bodies ("embryoid bodies").
- the hygromycin-resistant embryoid bodies are then selected using the Geneticin (G418) cell poison.
- the cells obtained are grown and examined for their composition (gene expression, proteins), their function and their contractile properties.
- Embryonic stem cells (ESC) or primordial germ cells (EGC) of various origins, including those from mice, rats, pigs, cattle, dogs, rabbits, hamsters, including human cells, can be used as the starting material.
- the vectors according to the invention and the sequence of the cell selection process are shown in Figure 1.
- the invention further relates to cells which, in addition to the vectors a) and b) mentioned, also contain therapeutic genes such as, for. B. contain the angiogenesis factors VEGF or bFGF, which were introduced by viral or non-viral gene transfer.
- the cell lines thus obtained can - with or without viral sequences - for cell-mediated gene transplantation, in particular which are used to build healthy tissue and to support contractile functions.
- Another important use of the cell lines according to the invention is the in vitro testing of biologically active substances, in particular for the investigation of pharmacologically relevant substances or for the determination of toxic effects of exogenous active substances on cardiac cells in culture. This saves animal experiments, particularly in screening programs, and fulfills urgent public demands for animal replacement models.
- the cell lines can also serve as vesicles for local gene transfer into the myocardium.
- the desired therapeutic genes are transfected by a viral, preferably with an adenovirus or an adenovirus-associated virus shuttle vector, or a non-viral gene transfer method.
- the genes are preferably packaged with the AAV vector pSub201.
- the invention makes it possible for the first time to treat heart muscle diseases with the aid of cellular gene transfer (gene therapy). This means considerable medical progress, in particular diseases such as ischemic and congenital cardiomyopathies can be treated with greater prospects of success in the future.
- the following elements are used to construct the vectors: 2.1 kb MLC-2v promoter (can be cloned with Kpnl and EcoRI), fusion gene ßgeo (can be cloned with BamHI), SV40-PolyA (can be cloned with Sacl) and Tk-hygromycin fusion gene in the bluescript KS- Vector. As shown in Figure 1, these elements become 2 vectors for cotransfection into pluripotent embryonic Stem cells created:
- Any ES cell line which differentiates into cardiomyocytes can be used as a pluripotent stem cell line (Wobus et al, Differentiation 48/1991 /, 173-182), e.g. B. line D3 (Doetschmann et al, J. Embryol. Exp. Morphol. 3/1985 /, 27-45).
- the D3 cells are cultivated on gelatinized plates with standardized culture medium on a feeder layer or in the presence of the recombinant "leukemia inhibiting factor" (LIF).
- LIF corresponds to the "Differentiation Inhibiting Factor", which prevents the differentiation of the ES cells and promotes the cell division of the pluripotent ES cells.
- the DNA constructs shown in Figure 1 are introduced into the ES cells by electroporation.
- the vectors are linearized using restriction digestion and transfected in a concentration of 25 ⁇ g / ml using electroporation.
- the pluripotent ES cell lines are then expanded in the LIF / ES cell medium. Only the thymidine kinase promoter is active in the undifferentiated ES cells, which leads to expression of the hygromycin resistance gene. By adding hygromycin B, the ES cells are selected for the incorporation of the foreign DNA (positive selection).
- the differentiation system of the hanging drop is used to obtain "embryoid bodies".
- a cell suspension containing about 400-600 ES cells in 20 l is pipetted onto the lids of petri dishes which are filled with a physiological buffer solution.
- the cells collect in drops and form after two to three days of incubation "embryoid bodies”. After 7 days, the "embryoid bodies” are transferred to microtest tissue culture dishes, where they adhere to the gelatin-coated substrate.
- various cell types, including cardiac muscle cells grow out ( Figure 2). Two to ten days after plating, about 80 to 90% of the adult "embryoid bodies” colonies contain spontaneously and synchronously contracting cardiac muscle cells (Wobus et al, 1991).
- the MLC-2v promoter is active in these embryonic heart muscle cells. If the MLC-2v-ßgeo vector is successfully transfected and integrated into the genome of the ES cells, the fusion gene ß-galactosidase / neomycin is expressed.
- the cardiomyocyte cells which are of clonal origin, can be identified by blue staining in the ⁇ -galactosidase assay.
- the positive ES cell clones which contain both the Tk-hygromycin and the MLC-2v-ßgeo fusion gene, are expanded again and some are brought under the conditions described above to differentiate into "embryoid bodies".
- the cell poison Geneticin G418 is added to the "embryoid bodies" in a concentration of 300 ⁇ g / ml.
- the embryonic (cardiomyocytic or cardiomyoblastic) heart muscle cells are selected at an early stage.
- the cells obtained are examined for tissue-specific gene expression, functional properties with the aid of electrophysiological techniques and for their contractile properties; the composition of the contractile proteins is characterized using appropriate monoclonal antibodies.
- divisible beating cells can then be transferred to adult and neonatal cardiomyopathic mdx mice after thoracomy and direct injection into the myocardium. 5a
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4441327 | 1994-11-22 | ||
DE4441327A DE4441327C1 (de) | 1994-11-22 | 1994-11-22 | Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung |
PCT/DE1995/001699 WO1996016163A2 (de) | 1994-11-22 | 1995-11-21 | Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0787182A2 true EP0787182A2 (de) | 1997-08-06 |
Family
ID=6533720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95940117A Withdrawn EP0787182A2 (de) | 1994-11-22 | 1995-11-21 | Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung |
Country Status (4)
Country | Link |
---|---|
US (1) | US5928943A (de) |
EP (1) | EP0787182A2 (de) |
DE (1) | DE4441327C1 (de) |
WO (1) | WO1996016163A2 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
EP0862644A2 (de) * | 1995-11-17 | 1998-09-09 | Franz, Wolfgang-M., Dr. | Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen |
US6051008A (en) | 1996-12-02 | 2000-04-18 | Angiotrax, Inc. | Apparatus having stabilization members for percutaneously performing surgery and methods of use |
US6120520A (en) | 1997-05-27 | 2000-09-19 | Angiotrax, Inc. | Apparatus and methods for stimulating revascularization and/or tissue growth |
US6102926A (en) | 1996-12-02 | 2000-08-15 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use |
JP2002507407A (ja) * | 1998-03-23 | 2002-03-12 | ザイモジェネティクス,インコーポレイティド | 心臓由来幹細胞 |
US20030113301A1 (en) * | 1999-07-23 | 2003-06-19 | Albert Edge | Muscle cells and their use in cardiac repair |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US8075881B2 (en) | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
DE10014690A1 (de) * | 2000-03-24 | 2001-10-18 | Franz Wolfgang M | Verfahren zur Isolierung in vito differenzierter Körperzellen |
DE60134982D1 (de) | 2000-07-13 | 2008-09-04 | Abbott Cardiovascular Systems | Einbringungssystem für myokardiales, zellulares material |
US7862810B2 (en) * | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
AU2001284695A1 (en) * | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20110091428A1 (en) * | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
CA2431197C (en) * | 2000-12-27 | 2012-03-13 | Axiogenesis Ag | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
DE10136702B4 (de) | 2000-12-27 | 2004-04-22 | Axiogenesis Ag | System zur zell- und entwicklungsspezifischen Selektion differenzierender embryonaler Stammzellen, adulter Stammzellen und embryonaler Keimbahnzellen |
EP1367899A4 (de) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotente adulte stammzellen, ausgangsmaterial dafür, verfahren zu ihrer gewinnung und erhaltung, differenzierungsmethoden dafür, verfahren zu ihrer verwendung, sowie von ihnen stammende zellen |
WO2003001202A1 (en) * | 2001-06-25 | 2003-01-03 | Cardion Ag | Methods and cell populations for identifying and validating genomic targets, and for drug screening |
US7732199B2 (en) | 2001-07-12 | 2010-06-08 | Geron Corporation | Process for making transplantable cardiomyocytes from human embryonic stem cells |
JP2004535199A (ja) * | 2001-07-12 | 2004-11-25 | ジェロン コーポレイション | ヒト多能性幹細胞から産生される心筋細胞系譜の細胞 |
WO2003014361A1 (en) * | 2001-08-02 | 2003-02-20 | Altana Pharma Ag | Novel recombinant gene expression method by stop codon suppression |
DE10144326B4 (de) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Verfahren und System zur Überwachung eines Reifenluftdrucks |
US6893431B2 (en) | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
US8574195B2 (en) * | 2002-06-10 | 2013-11-05 | Advanced Cardiovascular Systems, Inc. | Systems and methods for detecting tissue contact and needle penetration depth using static fluid pressure measurements |
US7364567B2 (en) | 2002-06-10 | 2008-04-29 | Abbott Cardiovascular Systems Inc. | Systems and methods for detecting tissue contact and needle penetration depth |
BR0312764A (pt) * | 2002-07-26 | 2005-07-26 | Wisconsin Alumni Res Found | Cardiomiócitos funcionais originados de células-tronco embrionárias humanas |
US20040191225A1 (en) * | 2002-08-06 | 2004-09-30 | Dinsmore Jonathan H. | Injection system |
JP2004246317A (ja) * | 2002-12-20 | 2004-09-02 | Hitachi Ltd | 冷陰極型フラットパネルディスプレイ |
US9321997B2 (en) * | 2003-06-20 | 2016-04-26 | Axiogenesis Ag | Tissue modeling in embryonic stem (ES) cell system |
WO2005003320A2 (en) * | 2003-07-02 | 2005-01-13 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
US8308708B2 (en) | 2003-07-15 | 2012-11-13 | Abbott Cardiovascular Systems Inc. | Deployment system for myocardial cellular material |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US20050214938A1 (en) * | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
US7452718B2 (en) * | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
EP1740945B1 (de) | 2004-04-07 | 2018-09-19 | Ncardia AG | Nichtinvasive, in-vitro-funktionelle gewebetestsysteme |
JP4814875B2 (ja) | 2004-05-11 | 2011-11-16 | アキシオジェネシス エージー | invitro分化細胞に基づく薬物発見のための検定 |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US9062289B2 (en) | 2005-06-22 | 2015-06-23 | Asterias Biotherapeutics, Inc. | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
WO2008063675A2 (en) * | 2006-11-24 | 2008-05-29 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
JP2011510658A (ja) * | 2008-01-30 | 2011-04-07 | ジェロン・コーポレーション | 幹細胞由来心筋細胞を培養するための合成表面 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5275942A (en) * | 1991-12-16 | 1994-01-04 | The University Of North Carolina At Chapel Hill | Mammalian cell-based DNA libraries |
-
1994
- 1994-11-22 DE DE4441327A patent/DE4441327C1/de not_active Expired - Fee Related
-
1995
- 1995-11-21 US US08/849,706 patent/US5928943A/en not_active Expired - Lifetime
- 1995-11-21 EP EP95940117A patent/EP0787182A2/de not_active Withdrawn
- 1995-11-21 WO PCT/DE1995/001699 patent/WO1996016163A2/de active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO9616163A3 * |
Also Published As
Publication number | Publication date |
---|---|
DE4441327C1 (de) | 1995-11-09 |
WO1996016163A2 (de) | 1996-05-30 |
WO1996016163A3 (de) | 1996-07-18 |
US5928943A (en) | 1999-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4441327C1 (de) | Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung | |
DE69937347T2 (de) | Regulierung der hämatopoietischen stammzelldifferenzierung durch verwendung von menschlichen mesenchymalen stammzellen | |
EP1948789B1 (de) | Verfahren zur herstellung von permanenten humanen zelllinien | |
DE60020855T2 (de) | Bedingte immortalisierung von zellen | |
DE60033663T2 (de) | Verfahren zur herstellung einer nicht-differenzierten kultur von vogelzellen mittels primordialer keimzellen | |
Dribin et al. | Conditioned medium enhances neuritic outgrowth from rat spinal cord explants | |
DE69831957T3 (de) | Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen | |
DE69937243T2 (de) | Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1 | |
AU2002330465B2 (en) | Screening method for a reprogramming agent, reprogramming agent screened by the method, method for using the reprogramming agent, method for differentiating an undifferentiated fusion cell, and production method of cells, tissues and organs. | |
WO2006044492A2 (en) | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome | |
EP0263908B1 (de) | Verfahren zur Herstellung von Proteinen mittels induzierbarer Expressionssysteme in in-vivo-vermehrten, genetisch modifizierten eukaryotischen Wirtszellen | |
WO1999001552A1 (de) | Fluoreszierende proteine als zelltypspezifische reporter | |
JPH11507230A (ja) | 細胞の不死化及び脱不死化 | |
DE69736858T2 (de) | Unsterbliche vogelzellen | |
DE69731310T2 (de) | Verfahren zum unsterblich machen von zellen | |
DE60021404T2 (de) | System zur herstellung von proteinen | |
DE60208066T2 (de) | Promotoren zur kontrolle der zelldifferenzierung | |
Hashimoto et al. | Cooperative transcription activation between Ad1, a CRE-like element, and other elements in the CYP11B gene promoter | |
WO1994016065A1 (en) | Producing cells for transplantation to reduce host rejection and resulting cells | |
DE69836853T2 (de) | Etablierte Mikrogliazellen | |
Thi et al. | Proliferation and differentiation properties of permanent Schwann cell lines immortalized with a temperature-sensitive oncogene | |
Schilham et al. | Sox-4 gene is required for cardiac outflow tract formation and pro-B lymphocyte expansion | |
DE19716098A1 (de) | Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden | |
WO2002009507A1 (de) | Somatischer klonierungs-gentransfer zur produktion von rekombinanten proteinen, zellen und organen | |
US20030109037A1 (en) | Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970530 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010409 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CARDION AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSTITUT FUER PFLANZENGENETIK UND KULTURPFLANZENF |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAA | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOS REFN |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
17Q | First examination report despatched |
Effective date: 20010409 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LEIBNIZ-INSTITUT FUER PFLANZENGENETIK UND KULTURPF |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070712 |